An Open-label, Single-dose Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2016
At a glance
- Drugs Esketamine (Primary) ; Esketamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 01 Sep 2016 Status changed from recruiting to completed.
- 03 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2016.
- 03 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Aug 2016.